Petros Pharmaceuticals, Inc. (PTPI) Research
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Market snapshot
- Symbol
- PTPI
- Price
- $0.01
- Day change
- 0.00%
- Market cap
- $187.0K
- P/E ratio
- 0.09x
- 52-week range
- 0.002-0.04
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
Peer companies
Recent insider activity
- WALKER WAYNE REMELL — A-Award (375000 shares) on 2026-06-05
- Boctor Fady — A-Award (375000 shares) on 2026-06-05
- Bernstein Bruce — A-Award (1875000 shares) on 2026-06-05
- Silverman Joshua — A-Award (4375000 shares) on 2026-06-05
- Boctor Fady — A-Award (500000 shares) on 2026-01-02
Open Petros Pharmaceuticals, Inc. (PTPI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.